Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: A diagnostic dilemma with immunohistochemical evaluation of 2 cases

International Journal of Surgical Pathology

Volumn 15, Issue 2, 2007, Pages 213-218

  Martińez Rodríguez, Miguel ^a   Ramos, David ^a   Soriano, Pilar ^a   Subramaniam, Manish ^a   Navarro, Samuel ^a   Llombart Bosch, Antonio ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Adenocarcinoma of prostate; Collision tumor; Differential diagnosis; Urothelial carcinoma

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; ISOMERASE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOCARCINOMA; AGED; ARTICLE; BLADDER TUMOR; CASE REPORT; DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; METABOLISM; MULTIPLE CANCER; PATHOLOGY; PROSTATE TUMOR; TRANSITIONAL CELL CARCINOMA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; NEOPLASMS, MULTIPLE PRIMARY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 34249705282     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896906295822     Document Type: Article

References (11)

1. Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA, Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2004;171:646-651. (Pubitemid 38090448)
2. Overstreet K, Haghighi P. Urothelial and prostate carcinoma metastasizing to the same lymph node. Arch Pathol Lab Med. 2001;125:1354-1357.
3. Mhawech P, Uchida T, Pelte MF. Immunohisto chemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33:1136-1140. (Pubitemid 35416713)
4. Nguyen PL, Schultz D, Renshaw AA, et al. The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol. 2004;22:295-299. (Pubitemid 38993306)
5. Huang Q, Chu PG, Lau SK, Weiss LM. Urothelial carcinoma of the urinary bladder with a component of acinar/tubular type differentiation simulating prostatic adenocarcinoma. Hum Pathol. 2004; 35:769-773. (Pubitemid 38881090)
6. Oliai B, Kahane H, Epstein JI. A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy. Am J Surg Pathol. 2001;25:794-801. (Pubitemid 32496870)
7. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186-1191.
8. Mai K, Ford JC, Morash C, Gerridzen R. Primary and secondary prostatic adenocarcinoma of the urinary bladder. Hum Pathol. 2001;32:434-440. (Pubitemid 32378306)
9. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005;47:1-16. (Pubitemid 40978808)
10. Bassily N, Vallorosi CJ, Akdas G, Montie JE, Rubin MA. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol. 2000;113:383-388. (Pubitemid 30217386)
11. Varma M, Morgan M, Amin MB, Wozniak S, Jasani B. High molecular weight cytokeratin antibody (clone 34βE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer. Histopathology. 2003;42:167-172. (Pubitemid 36237849)